期刊
TRENDS IN IMMUNOLOGY
卷 35, 期 7, 页码 290-298出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.it.2014.05.002
关键词
-
类别
资金
- Sam Keen Foundation
- UCL NIHR Biomedical Research Centre
- MRC
- Cancer Research UK
- Cancer Research Institute (USA)
- Association for International Cancer Research (AICR)
- EU FP7 award
- Cancer Research UK [12100] Funding Source: researchfish
Immunomodulatory antibodies influence the direction and magnitude of immune responses against cancer. Significant efficacy has been demonstrated across multiple solid tumour types within clinical trials. Recent preclinical studies indicate that successful outcome relies upon mechanistic activity extending beyond simple receptor stimulation or blockade. In addition to blocking co-inhibitory signals in secondary lymphoid organs, cytotoxic T-lymphocyte antigen (CTLA)-4 antibodies mediate depletion of tumour-infiltrating regulatory T cells by antibody-dependent cellular cytotoxicity (ADCC). This mechanism appears to be common to other immunomodulatory antibodies including those targeting OX40 and glucocorticoid-induced TNFR-related protein (GITR). If verified in the human setting, these findings have significant implications for antibody design, biomarker discovery, and the development of synergistic combinatorial therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据